@article{franck:hal-03789365,
TITLE = {Switch from intravenous to subcutaneous infliximab in inflammatory bowel disease: Which consequences from a pharmacokinetic perspective?},
AUTHOR = {Franck, B. and Verdier, M.C. and Bellissant, E. and Bouguen, G. and Lemaitre, F. and Tron, C.},
URL = {https://hal.science/hal-03789365},
JOURNAL = {Fundamental \& Clinical Pharmacology},
PUBLISHER = {Wiley},
VOLUME = {36},
PAGES = {43-43},
YEAR = {2022},
KEYWORDS = {infliximab ; sub-cutaneous ; exposure ; therapeutic drug monitoring ; inflammatory bowel disease},
HAL_ID = {hal-03789365},
HAL_VERSION = {v1},
}